- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Sanford Burnham Prebys Medical Discovery Institute
Headquarters: La Jolla, CA, United States of America
Website: http://www.sbpdiscovery.org
Year Founded: 1976
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Aug 30, 2023
Management Tracks
Domain partner Dovey passes away
Longtime VC led investments in more than 200 life sciences companies
BioCentury | Aug 16, 2023
Regulation
Aug. 15 Quick Takes: April PDUFA for Carvykti in earlier stage MM
Plus: Nucleic acid company Impilo launches to treat solid tumors and updates from Galecto, Design, Arcellx, Amicus, Alaunos, Lidao
BioCentury | Oct 1, 2022
Discovery & Translation
An anti-IgE protein-bacteria combo for food allergy; predicting COVID mutants, Lasker winners and more
BioCentury’s roundup of translational news
BioCentury | Sep 9, 2022
Management Tracks
Misciattelli becomes CEO of Aavantgarde
Plus new CMO, SVP of clinical development at Alumis, and updates from Vertex, Third Rock, AiCuris and more
BioCentury | Mar 13, 2021
Translation in Brief
NIH identifies antisense oligos to treat progeria; plus epigenetic gene therapies for chronic pain and Cend’s pancreatic cancer therapy
BioCentury’s roundup of translational news
BioCentury | Jan 30, 2021
Distillery Therapeutics
Epigenetic repressors of repetitive elements as cancer targets
DISEASE CATEGORY: Cancer
INDICATION: Brain cancer; breast cancer Inhibiting the histone methyltransferase SUV39H1 or FBXO44, which recruits the epigenetic enzyme, to reactivate expression of
INDICATION: Brain cancer; breast cancer Inhibiting the histone methyltransferase SUV39H1 or FBXO44, which recruits the epigenetic enzyme, to reactivate expression of
BioCentury | Aug 27, 2020
Distillery Therapeutics
Promoting expression of immune targets IFI16 and NLRC5 for melanoma
DISEASE CATEGORY: Cancer
INDICATION: Melanoma Promoting the expression of immune genes IFI16 and NLRC5 directly, or indirectly by inhibiting epigenetic protein PRMT5, could treat melanoma. In
INDICATION: Melanoma Promoting the expression of immune genes IFI16 and NLRC5 directly, or indirectly by inhibiting epigenetic protein PRMT5, could treat melanoma. In
BioCentury | Jun 27, 2020
Product Development
Modeling harmony: learning from preclinical coordination of COVID-19 countermeasures
How COVID-19 consortia are harmonizing preclinical testing of antivirals, mAbs and vaccines
BioCentury | Jun 6, 2020
Translation in Brief
Engineered bacteria for targeted bacterial killing; plus Cas12a base editors, base editing to restore hearing and more
BioCentury’s roundup of preclinical news
Items per page:
1 - 10 of 46